AwardTape · Defense awards · Inhalon Biopharma, Inc
Inhalon Biopharma, Inc: $5.4M in DoD and DHS awards
Inhalon Biopharma, Inc holds 2 DoD and DHS prime awards with $5.4M obligated Sep 16, 2024 to Sep 22, 2025. Largest category: Health R&D at $5.4M; largest buyer: Defense Health Agency at $5.4M.
| Obligated FY2024+ | $5.4M |
|---|---|
| Awards | 2 |
| FY2024 | $2.2M |
| FY2025 | $3.2M |
| FY2026 to date | $0 |
| Lifetime obligated on these awards | $5.4M |
| Parent company (as reported) | Inhalon Biopharma, Inc |
| First and latest action | Sep 16, 2024 · Sep 22, 2025 |
| # | Category | Obligated FY2024+ | Awards | Share |
|---|---|---|---|---|
| 1 | Health R&D | $5.4M | 2 awards | 100% |
| # | Agency | Obligated FY2024+ | Awards | Share |
|---|---|---|---|---|
| 1 | Defense Health Agency | $5.4M | 2 awards | 100% |
| Award | Obligated FY2024+ | What | Agency | Category | Latest action |
|---|---|---|---|---|---|
| HT942525CE039 definitive contract | $3.2M | A phase 1 placebo-controlled dose-escalation safety and pharmacokinetic study of in-007, a nebulized, pan-sars ace2-decoy therapeutic for pandemic preparedness | Defense Health Agency | Health R&D | Sep 22, 2025 DoD 90d |
| HT942524C0076 definitive contract | $2.2M | Developing in-007 as a widely deployable inhaled treatment against pathogens utilizing human ace2 for viral attachment and entry | Defense Health Agency | Health R&D | Sep 4, 2025 DoD 90d |
Source: USAspending.gov prime award data (FPDS), DoD and DHS contracts, orders and IDVs with any action since Oct 1, 2023. Obligated FY2024+ sums the obligations on those actions; total obligated is the award's lifetime figure. DoD contract actions publish on USAspending about 90 days after signing (DFARS PGI 204.6), so the latest DoD actions here trail the calendar by about 3 months. Data as of Oct 9, 2026.
Terminal: filters, alerts and CSV export for this company's awards.
7 days free for first-time subscribers, then $49/mo. Card required. Cancel before day 8 and you pay nothing.
Start free trial